secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kiniksa Pharmaceuticals International, plc (KNSA)
CIK:        0001730430
Form:       8-K
Filed at:   2022-01-03T23:59:59+00:00
Accession:  0001104659-22-000429
Event type: leadership
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kiniksa appoints Eben Tessari as SVP, Chief Operating Officer
-------------------------------------------------------------

- Eben Tessari promoted to COO effective Jan 3, 2022; previously SVP Chief Business Officer.
- New employment agreement provides $444,960 base salary and 40% target annual bonus.
- Severance includes 9 months base salary plus $16,500 lump sum and 12-month equity acceleration.
- Tessari also subject to existing invention, non-disclosure, non-competition agreements.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1730430/000110465922000429/0001104659-22-000429-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1730430/000110465922000429/tm2136470d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-000429

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer